Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline

Qiagen N.V. (NYSE:QGEN) ranks among the oversold European stocks to buy. On March 13, Deutsche Bank upgraded Qiagen N.V. (NYSE:QGEN) to Buy from Hold, maintaining a $54 price target on the company’s shares. The firm stated that Qiagen’s stock had declined over 30% since late January’s M&A stories and accompanying downgrade, essentially pricing out any buyout premium.

According to the firm, the company’s 2026 outlook is back-end heavy, which is common among Diagnostics and Life Sciences competitors and is due in part to mechanical impacts reasonably reflected in current consensus estimates.

Qiagen N.V. (NYSE:QGEN) also outlined its strategy at the Barclays 28th Annual Global Healthcare Conference on March 10, emphasizing sustainable development objectives in the midst of a CEO transition.

Despite macroeconomic challenges and the temporary impact of discontinued products such as NeuMoDx, the company reiterated its 5% full-year growth estimate. Growth is likely to improve in the second half, boosted by the introduction of new sample-preparation products that could add up to 200 basis points to results.

Qiagen N.V. (NYSE:QGEN), based in the Netherlands, is a global leader in Sample-to-Insight solutions. The company provides technologies for extracting and analyzing DNA, RNA, and proteins from various samples.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.